Better mechanisms and clearer regulatory guidance are making way for new pain drugs, Quartet Medicine Inc. CEO Kevin Pojasek told BioWorld Today, talking about his firm's potential $595 million deal with Merck & Co. Inc. with a small-molecule approach to pain that targets the tetrahydrobiopterin (BH4) pathway.